Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience

Current Medical Research and Opinion

Volumn 32, Issue 11, 2016, Pages 1857-1861

  Simons, Leon A ^a   Ortiz, Michael ^a,b   Freedman, S Ben ^c,d   Waterhouse, Benjamin J ^e   Colquhoun, David ^f   Thomas, Gareth ^g  

^a ST VINCENT S HOSPITAL   (Australia)

^b Zitro Consulting Services   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ANZAC Medical Research Institute   (Australia)

^e Casting Solutions Pty   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g PFIZER INC   (United States)

Author keywords

Adherence; Anticoagulants; Medication persistence; NOAC drugs; Non valvular atrial fibrillation; Thromboembolic stroke; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; DEATH; DISEASE ASSESSMENT; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OCCLUSIVE CEREBROVASCULAR DISEASE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RIVAROXABAN; WARFARIN;

EID: 84982786949     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1218325     Document Type: Article

References (25)

1. P.A.Wolf, R.D.Abbott, W.B.Kannel Atrial fibrillation as an independent risk factor for stroke:the Framingham Study. Stroke 1991;22:983-8
2. L.Friberg, M.Rosenqvist, A.Lindgren,. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605
3. M.Gattellari, C.Goumas, R.Aitken,. Outcomes for patients with ischaemic stroke and atrial fibrillation:the PRISM Study (a program of research informing stroke management). Cerebrovasc Dis 2011;32:370-82
4. R.G.Hart, L.A.Pearce, M.I.Aguilar Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
5. J.B.Olesen, G.Y.Lip, J.Lindhardsen,. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation:a net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost 2011;106:739-49
6. V.Frykman, B.Beerman, L.Ryden, ; Medical Products Agency; Swedish Society of Cardiology. Management of atrial fibrillation:discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-9
7. S.B.Freedman, B.J.Gersh, G.Y.H.Lip Misperception of aspirin efficacy and safety may perpetuate anticoagulant underutilisation in atrial fibrillation. Eur Heart J 2015;36:653-6
8. T.Gomes, M.M.Mamdani, A.M.Holbrook,. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9
9. C.D.Bushnell, D.M.Olson, X.Zhao,. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-90
10. L.A.Simons, M.Ortiz, P.Germanos,. Persistence on warfarin in patients with atrial fibrillation:experience in Australia 2006–2009. Aust Fam Physic 2013;42:659-61
11. S.Schulman, B.Shortt, M.Robinson,. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
12. I.Savelieva, A.J.Camm Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32-47
13. R.Sauer, E.-M.Sauer, T.Bobinger,. Adherence to oral anticoagulation in secondary stroke prevention – the first year of direct oral anticoagulants. J Stroke Cerebrovasc Dis 2015;24:78-82
14. C.Martinez, A.Katholing, C.Wallenhorst,. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2015;115:31-9
15. A.J.Camm, F.J.Pinto, G.J.Hankey,. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice:barriers to and strategies for optimal implementation. Europace 2015;17:1007-17
16. C.A.Salazar, D.del Aguila, E.G.Cordova Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;3:CD009893
17. P.P.Kneeland, M.C.Fang Current issues in patient adherence and persistence:focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60
18. M.Gattellari, J.Worthington, N.Zwar,. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation. A representative survey of Australian family physicians. Stroke 2008;39:227-30
19. B.Arbit, J.C.Hsu Non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation and associated intracranial haemorrhage:a focussed review. Clin Cardiol 2015;38:684-91
20. H.-Y.Chang, M.Zhou, W.Tang,. Risk of gastrointestinal bleeding associated with oral anticoagulants:population based retrospective cohort study. BMJ 2015;350:h1585
21. S.Tamayo, W.F.Peacock, M.Patel,. Characterizing major bleeding in patients with nonvalvular atrial fibrillation:a pharmacovigilance study of 27467 patients taking rivaroxaban. Clin Cardiol 2014;38:63-8
22. H.Heidbuchel, P.Verhamme, M.Alings,. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
23. S.D.Saini, P.Schoenfeld, K.Kaulback,. Effect of medication dosing frequency on adherence in chronic disease. Am J Manag Care 2009;15:e22-3
24. C.I.Coleman, M.S.Roberts, D.M.Sobieraj,. Effect of dosing frequency on chronic cardiovascular disease medication adherence Curr Med Res Opin 2012;228:669-80
25. B.Vrijens, H.Heidbuchel Non-vitamin K antagonist oral anticoagulants:considerations on once- vs twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23